Last reviewed · How we verify
Placebo for AG-120
This drug is a placebo, meaning it has no active therapeutic effect.
This drug is a placebo, meaning it has no active therapeutic effect. Used for Acute myeloid leukemia.
At a glance
| Generic name | Placebo for AG-120 |
|---|---|
| Sponsor | Stichting Hemato-Oncologie voor Volwassenen Nederland |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
As a placebo, AG-120 does not interact with any molecular targets or biological pathways. It is used as a control in clinical trials to compare the efficacy of the active treatment.
Approved indications
- Acute myeloid leukemia
Common side effects
- Injection site reaction
Key clinical trials
- Ivosidenib as Post-HSCT Maintenance for AML (PHASE2)
- Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation (PHASE3)
- Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy (PHASE3)
- A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy (PHASE3)
- Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for AG-120 CI brief — competitive landscape report
- Placebo for AG-120 updates RSS · CI watch RSS
- Stichting Hemato-Oncologie voor Volwassenen Nederland portfolio CI